0001610717-24-000239.txt : 20240516
0001610717-24-000239.hdr.sgml : 20240516
20240516175124
ACCESSION NUMBER: 0001610717-24-000239
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240514
FILED AS OF DATE: 20240516
DATE AS OF CHANGE: 20240516
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hata Yujiro S
CENTRAL INDEX KEY: 0001649119
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38915
FILM NUMBER: 24957090
MAIL ADDRESS:
STREET 1: C/O XENCOR, INC.
STREET 2: 111 WEST LEMON AVENUE
CITY: MONROVIA
STATE: CA
ZIP: 91016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc.
CENTRAL INDEX KEY: 0001676725
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 474268251
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-443-6209
MAIL ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Ideaya Biosciences, Inc.
DATE OF NAME CHANGE: 20160609
4
1
form4.xml
X0508
4
2024-05-14
0001676725
IDEAYA Biosciences, Inc.
IDYA
0001649119
Hata Yujiro S
C/O IDEAYA BIOSCIENCES, INC.
7000 SHORELINE COURT, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
true
true
President and CEO
true
Common Stock
2024-05-14
4
M
0
56711
4.31
A
734598
D
Common Stock
2024-05-14
4
S
0
54408
41.6011
D
680190
D
Common Stock
2024-05-14
4
S
0
2303
41.8357
D
677887
D
Common Stock
2024-05-15
4
M
0
83856
4.31
A
761743
D
Common Stock
2024-05-15
4
S
0
53592
42.5741
D
708151
D
Common Stock
2024-05-15
4
S
0
29761
43.4775
D
678390
D
Common Stock
2024-05-15
4
S
0
503
44.1179
D
677887
D
Common Stock
2024-05-16
4
M
0
34433
4.31
A
712320
D
Common Stock
2024-05-16
4
S
0
30084
41.7333
D
682236
D
Common Stock
2024-05-16
4
S
0
4349
42.366
D
677887
D
Stock Option (right to buy)
4.31
2024-05-14
4
M
0
56711
0
D
2028-02-26
Common Stock
56711
167743
D
Stock Option (right to buy)
4.31
2024-05-15
4
M
0
83856
0
D
2028-02-26
Common Stock
83856
83887
D
Stock Option (right to buy)
4.31
2024-05-16
4
M
0
34433
0
D
2028-02-26
Common Stock
34433
49454
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 22, 2023.
This transaction was executed in multiple trades in prices ranging from $40.815 to $41.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $41.81 to $41.945, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $42.08 to $43.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $43.09 to $43.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $44.10 to $44.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $41.2651 to $42.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $42.26 to $42.595, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares subject to the option are fully vested and exercisable.
/s/ Jason Throne, as Attorney-in-Fact for Yujiro Hata
2024-05-16